Intuitive Surgical, Inc. $ISRG Stake Raised by Simplify Asset Management Inc.

Simplify Asset Management Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 92.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 14,740 shares of the medical equipment provider’s stock after purchasing an additional 7,100 shares during the quarter. Intuitive Surgical accounts for 0.1% of Simplify Asset Management Inc.’s investment portfolio, making the stock its 25th biggest position. Simplify Asset Management Inc.’s holdings in Intuitive Surgical were worth $8,348,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. First National Trust Co raised its holdings in shares of Intuitive Surgical by 1.7% during the fourth quarter. First National Trust Co now owns 14,328 shares of the medical equipment provider’s stock valued at $8,115,000 after buying an additional 235 shares during the last quarter. Praxis Capital Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $510,000. North Star Asset Management Inc. increased its stake in shares of Intuitive Surgical by 1.9% during the fourth quarter. North Star Asset Management Inc. now owns 23,667 shares of the medical equipment provider’s stock valued at $13,404,000 after acquiring an additional 443 shares during the period. Darden Wealth Group Inc acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $227,000. Finally, Shelter Rock Management LLC acquired a new position in shares of Intuitive Surgical during the fourth quarter valued at approximately $263,000. Institutional investors own 83.64% of the company’s stock.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 500 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $473.46, for a total value of $236,730.00. Following the transaction, the director owned 239 shares in the company, valued at approximately $113,156.94. The trade was a 67.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Myriam Curet sold 105 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $493.95, for a total transaction of $51,864.75. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,701 shares of company stock valued at $2,783,807 in the last 90 days. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $438.10 on Monday. The firm has a market cap of $155.16 billion, a price-to-earnings ratio of 53.10, a price-to-earnings-growth ratio of 3.50 and a beta of 1.51. Intuitive Surgical, Inc. has a 1 year low of $417.74 and a 1 year high of $603.88. The firm’s 50 day moving average price is $458.62 and its two-hundred day moving average price is $510.37.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.42. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The firm’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.81 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ISRG. Piper Sandler lowered their price objective on shares of Intuitive Surgical from $620.00 to $580.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. HSBC lowered their price objective on shares of Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Citigroup upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price objective on the stock in a research note on Wednesday, March 11th. BTIG Research reiterated a “buy” rating and set a $574.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, April 22nd. Finally, Zacks Research lowered shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Nineteen analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $579.33.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive unveiled more than 100 upcoming upgrades for its da Vinci 5 robotic surgery system, including improved force-feedback tools, telecollaboration features, and security/reliability enhancements, which could strengthen the company’s competitive moat and support future procedure growth. Intuitive Surgical’s Da Vinci 5 Upgrades Aim To Deepen Moat For Investors
• Positive Sentiment: Intuitive also announced innovations tied to its “Quintuple Aim” strategy, reinforcing product development momentum and the company’s push to improve surgeon autonomy and operating-room efficiency. Intuitive Announces Innovations to Advance Quintuple Aim
• Positive Sentiment: Wall Street commentary remains moderately optimistic, with analysts still bullish on Intuitive Surgical’s long-term prospects despite recent underperformance versus the broader market. Are Wall Street Analysts Bullish on Intuitive Surgical Stock?
• Neutral Sentiment: Investor interest continues around the SP platform, where strong procedure growth suggests an important future opportunity, but it remains unclear whether this is true addressable-market expansion or mostly a shift within existing robotic procedures. ISRG’s SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
• Neutral Sentiment: There was also minor insider selling by an executive, but the transactions were very small and made under a pre-arranged 10b5-1 plan, so the signal for investors is limited. Mark Brosius insider transaction
• Negative Sentiment: The stock has also been hurt by recent weakness after earnings, with market commentary noting a roughly 7% decline since the last report, reflecting concern that the shares may need more proof of sustained acceleration. Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
• Negative Sentiment: Several articles also point out that ISRG has significantly lagged the market over the past six months, which may be keeping valuation-sensitive investors on the sidelines. 3 Big Reasons ISRG Should Be On Your Watchlist

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.